New PrEP studies will be a challenge, statisticians warn

nam/aidsmap, Published: 26 January 2016

Two statisticians involved in the PROUD and iPrEx trials of pre-exposure prophylaxis (PrEP) warn that future trials to test new PrEP drugs and formulations may be extremely difficult to design.

David Dunn of the UK Medical Research Council and David Glidden of the University of California, San Francisco say that statisticians will need to choose and analyse their trial population very carefully if they wish to be able to demonstrate meaningful results.

Read more here

Ipergay PrEP study results published

NAM , 02 December 2015

The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional comments and are notably cautious about not over-interpreting a study that only had 400 participants – very small for a prevention study – and an average of nine months’ follow-up.

It is the first, and so far only. randomised study to show that PrEP can be just as effective if it is given as an intermittent regimen that users only take when anticipating sex, rather than daily.

Read more here

PrEP Is Safe for People With Hepatitis B

AIDSMEDS, August 17, 2015

People with hepatitis B virus (HBV) can safely take Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP), as it does not lead to liver inflammation “flares” or other health problems when it is used or discontinued.

Read more here

Men at high risk for HIV may misjudge their vulnerability

Many gay, bisexual and queer men who are good candidates for a drug that prevents HIV don’t believe their risk of being infected with the virus is high enough to warrant the drug’s use.

Read more